Amgen Expands Cancer Portfolio with Up to $840M Dark Blue Therapeutics Deal

The acquisition, valued at up to $840 million, strengthens Amgen's oncology pipeline with a drug candidate addressing challenging leukemia markers, signaling commitment to hematologic cancers.

TCB TeamJan 7, 20264 min

Acquisition Details

Amgen agreed to acquire Dark Blue Therapeutics for up to $840 million, targeting a new cancer therapy.
The focus is on a small-molecule degrader that acts on MLLT1 and MLLT3 proteins, potential drivers of acute myeloid leukemia (AML).

Strategic Rationale

AML remains an area of high unmet medical need; this asset could complement Amgen’s existing cancer treatments.
The acquisition reflects ongoing investments by big pharma into innovative targeted therapies for blood cancers.

Outlook

Clinical development and regulatory review will determine the candidate's future success, with early data closely watched by investors and clinicians.

More details available at BioSpace.

The Catalyst Brief

Independent biotech intelligence, every week.

Get curated biotech intelligence across AI, industry, innovation, investment, medtech, and policy delivered to your inbox.